Up Therapeutics LLC

Up Therapeutics LLC is a partnership or limited liability partnership classified as a for-profit organization. It specializes in developing novel small molecule therapeutics, particularly targeting the proteasome pathway, as potential treatments for various cancers.

The federal grant awards received by Up Therapeutics LLC are aimed at advancing the development of its lead investigational drug candidate, UP284, for different oncology indications. UP284 is a proprietary inhibitor targeting RPN13, a protein in the 19S proteasome complex, with a novel mechanism of action designed to overcome limitations of licensed proteasome inhibitors. Through awards from the National Cancer Institute's Cancer Treatment Research program, Up Therapeutics has pursued research to evaluate UP284's safety, pharmacokinetics, and efficacy in preclinical models of ovarian cancer, glioblastoma, and quadruple-negative breast cancer. The studies involve assessing UP284's activity against tumor cell lines and patient-derived xenografts, conducting toxicology evaluations, optimizing formulation and manufacturing processes, and generating data to support IND applications to the FDA for clinical trials. Up Therapeutics has received grants from the National Cancer Institute totaling over $2.5 million for these research efforts focused on developing UP284 as a potential new targeted therapy for various solid tumor types with high unmet need.